Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 20/20 | 0.39 |
| ▸ | MMP1 | P03956 | 6/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP7 | P09237 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP14 | P50281 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7056173 | 0.93 | KMT2A (0.33) | MMP13 | |
| SCHEMBL7060283 | 0.93 | DRD2 (0.33) | MMP13 | |
| SCHEMBL7056516 | 0.93 | POLB (0.32) | MMP13 | |
| SCHEMBL7058728 | 0.88 | MMP13 (0.40) | MMP13MMP1MMP2MMP3MMP7 | |
| SCHEMBL7667714 | 0.87 | MMP13 (0.40) | MMP13MMP1MMP2MMP3MMP7 | |
| Hydrochloric Acid SCHEMBL7376259 | 0.87 | MMP13 (0.43) | MMP13MMP1MMP2MMP3MMP7 | |
| SCHEMBL7059651 | 0.87 | MMP13 (0.45) | MMP13MMP1MMP2MMP3MMP7 | |
| SCHEMBL7058994 | 0.84 | MMP13 (0.48) | MMP13MMP1MMP2MMP3MMP7 | |
| SCHEMBL7352584 | 0.81 | MMP13 (0.42) | MMP13MMP1MMP2MMP3MMP7 | |
| SCHEMBL7657258 | 0.80 | F2 (0.32) | MMP13MMP1MMP2MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6489324-B2 | TREATING STROKE, ARHTRITIS, CANCER, TISSUE ULCERATION, DECUBITIS ULCER, RESTENOSIS, PERIODONTAL DISEASE, EPIDERMOLYSIS BULLOSA, SCLERITIS, PSORIASIS, AIDS, SEPSIS, AND SEPTIC SHOCK. | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-6333324-B1 | FOR THERAPY AND PROPHYLAXIS OF MATRIX METALLOPROTEINASES (MMP) OR TUMOR NECROSIS FACTOR .ALPHA. (TNF.ALPHA.), MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |